apatinib combined with chemotherapy versus chemotherapy in second-line gastric cancer receiving prior anti-pd-1 therapy

Conditions: Gastric Cancer; Randomized Controlled Study

Summary: the study is a multicenter, open-label, randomized controlled clinical study. the purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric cancer receiving prior anti-pd-1 therapy.

60 patients who meet the inclusion criteria will receive apatinib combine with chemotherapy or chemotherapy until the disease progresses or intolerable. apatinib: initial dose: 500mg,oral,once a day, after meal (try to take the medicine at the same time each day)

Eligibility criteria:
inclusion criteria: 1. age: ≥18 years old, female or male; 2. pathologically diagnosed gastric or gastroesophageal junction adenocarcinoma (gej). 3. failure or intolerance of first-line chemotherapy which requires that the first-line chemotherapy regimen include the scheme based on anti-pd-1 drugs for no less than 2 months (definition of treatment failure: intolerence of toxic side effects; disease progression during treatment; or recurrence after the end of treatment.) note: (1)the treatment of each line advanced disease includes one or more drugs with a medication time ≥ 1 cycle. (2) early adjuvant/neo-adjuvant therapy is allowed. if recurrence occurs during adjuvant/neoadjuvant therapy or within ≤24 weeks after completion, adjuvant/neoadjuvant therapy is considered to be a first-line pre-systemic chemotherapy for advanced disease. (3) early-stage immunotherapy, combined chemotherapy or combined targeted drugs are allowed (except for vegfr inhibitors). 4. patients must have at least 1 lesion that is measurable using recist v1.1 criteria 5. ecog performance status 0-1. 6. an expected survival of \> 12 weeks. 7. has adequate sufficient organ and bone marrow functions. 8. patients whose adverse events caused by previous treatment have recovered to \<= ctcae 1 degree; and the interval between receiving nitroso or mitomycin ≥6 weeks; receiving other cytotoxic drugs, radiotherapy or surgery ≥ 4 weeks, and the wound has healed completely. 9. fertile female subjects must undergo a serum-negative pregnancy test within 72 hours before starting the study drug 10. patients have agreed and signed the informed consent. willingness and able to follow the planned visit, research treatment, laboratory examination and other test procedures. exclusion criteria: 1. it is known that it's allergic to any test drug and its excipients. 2. previously received anti-angiogenic therapy, such as ramucirumab and apatinib. 3. patients with uncontrolled large amount of exudate \[chest, pericardium, abdominal cavity\] 4. patients with partial or complete gastrointestinal obstruction. 5. hypertension, which cannot be well controlled by antihypertensive drugs (systolic blood pressure ≥ 140 mmhg or diastolic blood pressure ≥ 90 mmhg). 6. patients with uncontrolled clinical symptoms or diseases of the heart. 7. in the first 3 months of the study, patients who had significant clinical bleeding symptoms or had definite bleeding tendency; history of gastrointestinal perforation and/or fistulae within 6 months prior to medications. 8. long term use of aspirin, clopidogrel and other antiplatelet drugs, or warfarin and other anticoagulants; 9. received other therapy within 4 weeks. 10. the patients who received systemic treatment with chinese herbal medicine or immunomodulatory drugs 11. according to the research's judgement, there are patients who seriously endanger the safety of patients or affect the patients who complete.(such as uncontrolled hypertension、diabetes、thyroid disease, etc) 12. the patient has a serious or non healing wound or peptic ulcer or bone fracture; 13. a patient with other malignancies within 3 years. 14. patients whose adverse events (except hair loss) caused by previous treatment have not recovered to \<= ctcae 1 degree; 15. the researchers considered unsuitable for inclusion.

Keywords: apatinib chemotherapy prior anti-pd-1 therapy